Get the Stockscreener App
1.415
10.85%
0.125
Bioaffinity Technologies Inc stock is traded at $1.415, with a volume of 59,402.
It is up +10.85% in the last 24 hours and down -12.27% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$1.29
Open:
$1.31
24h Volume:
59,402
Relative Volume:
0.06
Market Cap:
$6.48M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-1.7469
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+21.19%
1M Performance:
-12.27%
6M Performance:
-83.74%
1Y Performance:
-95.03%
1-Day Range:
$1.31
$1.47
1-Week Range:
$1.17
$1.47
52-Week Range:
$1.1101
$46.53
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.44 | 5.80M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
621.03 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.80 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
716.95 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
243.25 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Cancer test lab keeps gold-standard accreditation after inspection - Stock Titan
2026 world cup star players explained: How bioAffinity Technologies Inc. Equity Warrant stock compares to growth peers2026 world cup usa national team round of 32 playmakers low block defense odds analysis preview - Улправда
bioAffinity Technologies Inc. (BIAF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 10.8% – Here’s What Happened - Defense World
bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 4.9% – Here’s What Happened - Defense World
What drives bioAffinity Technologies Inc Equity Warrant stock priceMarket Liquidity Analysis & High Yield Market Growth - earlytimes.in
Bearish Setup: Will bioAffinity Technologies Inc stock pay special dividendsCPI Data & Weekly Momentum Stock Picks - moha.gov.vn
bioAffinity Technologies reports transfer of Village Oaks Pathology ownership By Investing.com - Investing.com Nigeria
bioAffinity Technologies reports transfer of Village Oaks Pathology ownership - Investing.com
bioAffinity Updates Village Oaks Physician Succession Agreement - TipRanks
bioAffinity Technologies Announces Succession Agreement - TradingView — Track All Markets
Is bioAffinity Technologies Inc. stock a defensive play in 2025Trade Volume Summary & Community Trade Idea Sharing Platform - Улправда
Energy Moves: How bioAffinity Technologies Inc. Equity Warrant stock compares to growth peers2025 Technical Overview & Free Fast Gain Swing Trade Alerts - Улправда
Will bioAffinity Technologies Inc. stock return to pre crisis levelsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
Nasdaq Moves: Why bioAffinity Technologies Inc. stock could be next big winnerQuarterly Trade Report & Community Verified Watchlist Alerts - moha.gov.vn
How bioAffinity Technologies Inc. Equity Warrant stock trades during market volatilityJuly 2025 Chart Watch & Free Verified High Yield Trade Plans - Улправда
bioAffinity Technologies Earnings Notes - Trefis
Will bioAffinity Technologies Inc. Equity Warrant stock deliver strong dividend growthWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Market Catalysts: Is bioAffinity Technologies Inc. stock a defensive play in 2025Weekly Investment Recap & Safe Investment Capital Preservation Plans - Улправда
bioAffinity Technologies adjourns special shareholder meeting due to lack of quorum - Investing.com Nigeria
bioAffinity Technologies adjourns special shareholder meeting due to lack of quorum By Investing.com - Investing.com South Africa
Why bioAffinity Technologies Inc. Equity Warrant stock appeals to dividend seekers2025 Pullback Review & Fast Entry Momentum Trade Alerts - Улправда
bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum - TipRanks
bioAffinity Technologies Adjourns Special Meeting - TradingView — Track All Markets
How bioAffinity Technologies Inc. Equity Warrant stock compares to growth peersMarket Sentiment Summary & Consistent Return Strategy Ideas - Улправда
New Highs: Why bioAffinity Technologies Inc. stock could be next big winner - Улправда
Rate Hike: Can bioAffinity Technologies Inc. stock maintain growth trajectoryQuarterly Risk Review & Free High Accuracy Swing Entry Alerts - DonanımHaber
Is bioAffinity Technologies Inc. Equity Warrant stock dividend yield sustainablePortfolio Return Summary & Advanced Technical Analysis Signals - DonanımHaber
Trading Recap: Can bioAffinity Technologies Inc. Equity Warrant stock sustain revenue growthInsider Buying & AI Forecasted Stock Moves - DonanımHaber
Will bioAffinity Technologies Inc. stock outperform tech sector in 2025Earnings Trend Report & Safe Swing Trade Setups - DonanımHaber
Why bioAffinity Technologies Inc. stock could be next big winnerWeekly Investment Report & Smart Investment Allocation Insights - Улправда
What catalysts could drive bioAffinity Technologies Inc. Equity Warrant stock higherJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
bioAffinity Technologies, Inc. (BIAFW) Fundamental Analysis - Meyka
Reviewing bioAffinity Technologies (NASDAQ:BIAF) and Briacell Therap (NASDAQ:BCTX) - Defense World
Why bioAffinity Technologies Inc. stock could outperform in 2025Trade Risk Assessment & Growth Oriented Trading Recommendations - Newser
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss - MSN
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society - PharmiWeb.com
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - BioSpace
bioAffinity Technologies to Present at Cancer Roundtable - TipRanks
bioAffinity Technologies, Inc. to Present CyPath® Lung Test at ACS Roundtable - TradingView
Certain Warrants of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
Certain Convertible Preferred Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
1,375,102 Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com
bioAffinity Technologies Inc trading halted, volatility trading pause - MSN
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules (PR Newswire) - Aktiellt
Aug Action: Why bioAffinity Technologies Inc. stock could be next big winner - BỘ NỘI VỤ
bioAffinity Technologies Reports Strong Growth in Lung Test Revenue - MSN
How bioAffinity Technologies Inc. stock benefits from global expansionGDP Growth & Fast Exit Strategy with Risk Control - moha.gov.vn
Investment Review: Why retail investors pile into bioAffinity Technologies Inc. stockJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
Earnings roundup: Q3 rocky for bioAffinity and Spurs concessionaire - San Antonio Express-News
Is bioAffinity Technologies Inc Equity Warrant a good long term investmentMean Reversion Trades & Rapid Portfolio Gain - earlytimes.in
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):